💬 Editorial by Jeffrey L. Saver, MD: In #AcuteIschemicStroke, reperfusion therapies now reopen most occluded arteries, but many patients still have disabling outcomes after treatment. The LAIS trial indicates that loberamisal may improve 3-month disability-free recovery in patients who were not eligible for endovascular thrombectomy, supporting continued evaluation of #Neuroprotection alongside reperfusion strategies. ja.ma/4dsyab6

Among patients with #AcuteIschemicStroke treated within 48 hours of symptom onset, intravenous #Loberamisal was associated with a higher likelihood of full functional outcome at 90 days vs placebo. Adverse events, serious adverse events, and mortality were similar between groups, supporting further evaluation of neuroprotective and neuroreparative therapy in stroke care. 🔗 Read the full article: ja.ma/4dsy972

💬 Editorial by @JAMAplusTrials Editor in Chief Alison J. Huang, MD, MAS, Thomas G. Travison, PhD, and JAMA Senior Editor Derek C. Angus, MD, MPH: #PragmaticTrials are intended to support real-world clinical decision-making, but the term is used inconsistently across studies. A pragmatic orientation may improve the applicability of #ClinicalTrials to routine care, yet it does not justify weaker methods or reduced rigor. 📣 This September’s JAMA+ Trials Theme of the Month examines ongoing confusion and debate in pragmatic trial research, including how eligibility, intervention delivery, outcome assessment, and analysis align with pragmatic goals. Clearer design and reporting may help clinicians and health systems judge whether trial findings are usable in practice. 🔗 ja.ma/4gO0FCx

💬 Editorial by @JAMAplusTrials Editor in Chief Alison J. Huang, MD, MAS, Thomas G. Travison, PhD, and JAMA Senior Editor Derek C. Angus, MD, MPH: #PragmaticTrials are intended to support real-world clinical decision-making, but the term is used inconsistently across studies. A pragmatic orientation may improve the applicability of #ClinicalTrials to routine care, yet it does not justify weaker methods or reduced rigor. 📣 This September’s JAMA+ Trials Theme of the Month examines ongoing confusion and debate in pragmatic trial research, including how eligibility, intervention delivery, outcome assessment, and analysis align with pragmatic goals. Clearer design and reporting may help clinicians and health systems judge whether trial findings are usable in practice. 🔗 ja.ma/4x2jpmk